Anita Sveen

List of Publications by Year
in descending order

47 papers	2,300 citations	394421 19 h-index	233421 45 g-index
48 all docs	48 docs citations	48 times ranked	4399 citing authors

#	Article	IF	Citations
1	Multi-omics of 34 colorectal cancer cell lines - a resource for biomedical studies. Molecular Cancer, 2017, 16, 116.	19.2	232
2	CMScaller: an R package for consensus molecular subtyping of colorectal cancer pre-clinical models. Scientific Reports, 2017, 7, 16618.	3.3	229
3	Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study. The Lancet Gastroenterology and Hepatology, 2016, 1, 207-216.	8.1	227
4	Biomarker-guided therapy for colorectal cancer: strength in complexity. Nature Reviews Clinical Oncology, 2020, 17, 11-32.	27.6	195
5	ColoGuideEx: a robust gene classifier specific for stage II colorectal cancer prognosis. Gut, 2012, 61, 1560-1567.	12.1	179
6	Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover Potentially Targetable Cancer Cell Dependencies. Clinical Cancer Research, 2018, 24, 794-806.	7.0	177
7	ColoGuidePro: A Prognostic 7-Gene Expression Signature for Stage III Colorectal Cancer Patients. Clinical Cancer Research, 2012, 18, 6001-6010.	7.0	109
8	Combination therapies with HSP90 inhibitors against colorectal cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2019, 1871, 240-247.	7.4	81
9	Transcriptome instability in colorectal cancer identified by exon microarray analyses: Associations with splicing factor expression levels and patient survival. Genome Medicine, 2011, 3, 32.	8.2	73
10	Multilevel genomics of colorectal cancers with microsatellite instabilityâ€"clinical impact of JAK1 mutations and consensus molecular subtype 1. Genome Medicine, 2017, 9, 46.	8.2	71
11	Epigenetic disruption of miR-130a promotes prostate cancer by targeting SEC23B and DEPDC1. Cancer Letters, 2017, 385, 150-159.	7.2	70
12	Patient-Derived Organoids from Multiple Colorectal Cancer Liver Metastases Reveal Moderate Intra-patient Pharmacotranscriptomic Heterogeneity. Clinical Cancer Research, 2020, 26, 4107-4119.	7.0	68
13	Intra-patient Inter-metastatic Genetic Heterogeneity in Colorectal Cancer as a Key Determinant of Survival after Curative Liver Resection. PLoS Genetics, 2016, 12, e1006225.	3.5	64
14	Phospholipase C Isozymes Are Deregulated in Colorectal Cancer â€" Insights Gained from Gene Set Enrichment Analysis of the Transcriptome. PLoS ONE, 2011, 6, e24419.	2.5	58
15	Tumour-infiltrating CD8+ lymphocytes and colorectal cancer recurrence by tumour and nodal stage. British Journal of Cancer, 2019, 121, 474-482.	6.4	41
16	Prognostic, predictive, and pharmacogenomic assessments of <scp>CDX</scp>2 refine stratification of colorectal cancer. Molecular Oncology, 2018, 12, 1639-1655.	4.6	40
17	Long noncoding RNA <i>MIR31HG</i> is a <i>bona fide</i> prognostic marker with colorectal cancer cellâ€intrinsic properties. International Journal of Cancer, 2019, 144, 2843-2853.	5.1	33
18	Metastatic heterogeneity of the consensus molecular subtypes of colorectal cancer. Npj Genomic Medicine, 2021, 6, 59.	3.8	29

#	Article	IF	Citations
19	Anticipating the Clinical Use of Prognostic Gene Expression–Based Tests for Colon Cancer Stage II and III: Is Godot Finally Arriving?. Clinical Cancer Research, 2013, 19, 6669-6677.	7.0	27
20	Alternative splicing expands the prognostic impact of *KRAS* in microsatellite stable primary colorectal cancer. International Journal of Cancer, 2019, 144, 841-847.	5.1	26
21	Molecular correlates of sensitivity to PARP inhibition beyond homologous recombination deficiency in pre-clinical models of colorectal cancer point to wild-type TP53 activity. EBioMedicine, 2020, 59, 102923.	6.1	22
22	The exon-level biomarker *SLC39A14* has organ-confined cancer-specificity in colorectal cancer. International Journal of Cancer, 2012, 131, 1479-1485.	5.1	20
23	Gene expression profiles of CMS2-epithelial/canonical colorectal cancers are largely driven by DNA copy number gains. Oncogene, 2019, 38, 6109-6122.	5.9	20
24	High Concordance and Negative Prognostic Impact of RAS/BRAF/PIK3CA Mutations in Multiple Resected Colorectal Liver Metastases. Clinical Colorectal Cancer, 2020, 19, e26-e47.	2.3	20
25	Transcriptional and functional consequences of TP53 splice mutations in colorectal cancer. Oncogenesis, 2019, 8, 35.	4.9	19
26	Transcriptome instability as a molecular pan-cancer characteristic of carcinomas. BMC Genomics, 2014, 15, 672.	2.8	15
27	Novel RNA variants in colorectal cancers. Oncotarget, 2015, 6, 36587-36602.	1.8	15
28	Improved prognostication of glioblastoma beyond molecular subtyping by transcriptional profiling of the tumor microenvironment. Molecular Oncology, 2020, 14, 1016-1027.	4.6	15
29	Heterogeneous radiological response to neoadjuvant therapy is associated with poor prognosis after resection of colorectal liver metastases. European Journal of Surgical Oncology, 2019, 45, 2340-2346.	1.0	14
30	Technical differences between sequencing and microarray platforms impact transcriptomic subtyping of colorectal cancer. Cancer Letters, 2020, 469, 246-255.	7.2	12
31	Inferior survival for patients with malignant peripheral nerve sheath tumors defined by aberrant TP53. Modern Pathology, 2018, 31, 1694-1707.	5.5	11
32	Exploratory analyses of consensus molecular subtype-dependent associations of TP53 mutations with immunomodulation and prognosis in colorectal cancer. ESMO Open, 2019, 4, e000523.	4.5	11
33	Genomic and prognostic heterogeneity among *RAS/BRAF*^{V600E}/*TP53* co-mutated resectable colorectal liver metastases. Molecular Oncology, 2021, 15, 830-845.	4.6	11
34	De novo transcriptomic subtyping of colorectal cancer liver metastases in the context of tumor heterogeneity. Genome Medicine, 2021, 13, 143.	8.2	10
35	Spatial analysis and CD25-expression identify regulatory T cells as predictors of a poor prognosis in colorectal cancer. Modern Pathology, 2022, 35, 1236-1246.	5.5	8
36	Mutational dynamics and immune evasion in diffuse large B-cell lymphoma explored in a relapse-enriched patient series. Blood Advances, 2020, 4, 1859-1866.	5.2	7

#	Article	IF	Citations
37	Treatment outcomes and prognostic factors after chemoradiotherapy for anal cancer. Acta OncolÃ³gica, 2021, 60, 921-930.	1.8	7
38	Observed correlation between the expression levels of catalytic subunit, CÎ²2, of cyclic adenosine monophosphateâ€"dependent protein kinase and prostate cancer aggressiveness. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 111.e1-111.e8.	1.6	6
39	Prediction of relapse-free survival according to adjuvant chemotherapy and regulator of chromosome condensation 2 (RCC2) expression in colorectal cancer. ESMO Open, 2020, 5, e001040.	4.5	6
40	Increased sensitivity to SMAC mimetic LCL161 identified by longitudinal ex vivo pharmacogenomics of recurrent, KRAS mutated rectal cancer liver metastases. Journal of Translational Medicine, 2021, 19, 384.	4.4	6
41	TIN: An R Package for Transcriptome Instability Analysis. Cancer Informatics, 2015, 14, CIN.S31363.	1.9	4
42	Multiregional assessment of CIMP in primary colorectal cancers: Phenotype concordance but marker variability. International Journal of Cancer, 2021, 148, 1652-1657.	5.1	4
43	The expressed mutational landscape of microsatellite stable colorectal cancers. Genome Medicine, 2021, 13, 142.	8.2	4
44	Expressed prognostic biomarkers for primary prostate cancer independent of multifocality and transcriptome heterogeneity. Cancer Gene Therapy, 2022, 29, 1276-1284.	4.6	3
45	Multiplex immunohistochemistry of metastatic colorectal cancer and ex vivo tumor avatars. Biochimica Et Biophysica Acta: Reviews on Cancer, 2022, 1877, 188682.	7.4	1
46	Novel drug discovery by pharmacogenomic profiling of 36 colorectal cancer cell lines.. Journal of Clinical Oncology, 2016, 34, 604-604.	1.6	0
47	Mutational Dynamics and Evolutionary Divergence in DLBCL: A Call for Relapse Sampling. Blood, 2019, 134, 1497-1497.	1.4	0